Ginkgo Bioworks, a leader in cell programming and biosecurity, has successfully achieved the first milestone in its partnership with Merck, focused on improving biologic manufacturing processes. This milestone accomplishment triggers a $9 million research payment to Ginkgo and sets the stage for the next phase of the collaboration. The partnership aims to leverage Ginkgo’s expertise in strain engineering, high-throughput screening, and process development to refine production efficiencies in biologic manufacturing. According to Jason Kelly, CEO and Co-Founder of Ginkgo Bioworks, this collaboration highlights the impact of innovative technical solutions and the value of close teamwork between the two companies.
Ginkgo Bioworks operates a horizontal platform for cell programming, offering end-to-end services across industries such as pharmaceuticals, food, agriculture, and specialty chemicals. Additionally, its biosecurity division provides cutting-edge technologies for predicting and responding to biological threats. Merck, a global pharmaceutical giant, is renowned for its contributions to healthcare, particularly in life-saving therapies and biologics. This collaboration aligns with Merck’s commitment to advancing biologic manufacturing while reinforcing Ginkgo’s role as a key partner for leading pharmaceutical firms. Together, they aim to set new standards in biologic production processes.
